Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $708.00 at Royal Bank Of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective lifted by Royal Bank Of Canada from $704.00 to $708.00 in a report released on Wednesday morning,Benzinga reports. They currently have a sector perform rating on the biopharmaceutical company’s stock.

REGN has been the topic of a number of other reports. Sanford C. Bernstein boosted their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 27th. Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Rothschild & Co Redburn began coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They issued a “buy” rating and a $890.00 target price on the stock. Jefferies Financial Group boosted their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research note on Wednesday, August 27th. Finally, Bank of America boosted their price objective on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a research note on Wednesday. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $813.78.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $652.91 on Wednesday. The stock’s 50-day simple moving average is $579.44 and its 200-day simple moving average is $564.03. Regeneron Pharmaceuticals has a 52 week low of $476.49 and a 52 week high of $935.86. The company has a market capitalization of $69.20 billion, a price-to-earnings ratio of 15.63, a PEG ratio of 2.04 and a beta of 0.31. The company has a quick ratio of 3.72, a current ratio of 4.82 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating the consensus estimate of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business’s revenue was up .9% on a year-over-year basis. During the same period in the previous year, the business earned $12.46 earnings per share. As a group, analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.43%.

Institutional Trading of Regeneron Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Grey Fox Wealth Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $93,000. Seizert Capital Partners LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 14.9% in the third quarter. Seizert Capital Partners LLC now owns 98,790 shares of the biopharmaceutical company’s stock valued at $55,547,000 after purchasing an additional 12,810 shares during the period. Sage Mountain Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $514,000. Jackson Thornton Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $519,000. Finally, QTR Family Wealth LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $227,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.